3-氯-N-(4-氯苄基)丙胺 | 103038-67-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-N-(4-氯苄基)丙胺
• 英文名称: N-(4-chlorobenzyl)-3-chloropropanamide
• 英文别名: 3-chloro-propionic acid-(4-chloro-benzylamide)；3-Chlor-propionsaeure-(4-chlor-benzylamid)；3-chloro-N-(4-chlorobenzyl)propanamide；3-chloro-N-[(4-chlorophenyl)methyl]propanamide
• CAS: 103038-67-1
• 化学式: C₁₀H₁₁Cl₂NO
• 分子量: 232.109
• InChiKey: CJINUSIFYWTQPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-氯-N-(4-氯苄基)丙胺 、 5-(吡啶-4-基)-1,3,4-噻二唑-2-硫醇 在 sodium ethanolate 作用下， 以 乙醇 、 水 为溶剂， 反应 8.0h， 以59%的产率得到N-(4-chlorobenzyl)-3-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-ylthio)propanamide
  参考文献：
  名称：

  Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis

  摘要：

  Multi-drug resistant (MDR) and extremely drug resistant (XDR) Mycobacterium tuberculosis strains have turned tuberculosis (TB) as "on the verge of eradication" to "most life threatening" disease. Furthermore, synergy with HIV and other immunosuppressive disease have strengthened its prevalence. This research reports small molecule anti-infectives which are specifically potent against several strains and isolates of TB. The hit compound 7f has also proved to be active against almost 25 clinical isolates comparable to marketed anti-TB agents. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.07.039
• 作为产物：
  描述：

  对氯苄胺 、 3-氯丙酰氯 在 potassium carbonate 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 3-氯-N-(4-氯苄基)丙胺
  参考文献：
  名称：

  [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES
  [FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  本发明涉及公式（I）的新化合物，以及其药用盐或溶剂和它们的用途。

  公开号：

  WO2015193255A1

文献信息

• Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
  申请人：UNIVERSITE DE LILLE 2 DROIT ET SANTE

  公开号：US10179761B2

  公开（公告）日：2019-01-15

  The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

  本发明涉及新型式 (I) 化合物、其药学上可接受的盐或溶液及其用途。
• COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES
  申请人：Université de Lille 2 Droit et Santé

  公开号：EP3154934A1

  公开（公告）日：2017-04-19
• [EN] COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LILLE II DROIT & SANTE

  公开号：WO2015193255A1

  公开（公告）日：2015-12-23

  The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.

  本发明涉及公式（I）的新化合物，以及其药用盐或溶剂和它们的用途。
• Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis
  作者：Niranjan S. Mahajan、S.C. Dhawale

  DOI：10.1016/j.ejmech.2015.07.039

  日期：2015.9

  Multi-drug resistant (MDR) and extremely drug resistant (XDR) Mycobacterium tuberculosis strains have turned tuberculosis (TB) as "on the verge of eradication" to "most life threatening" disease. Furthermore, synergy with HIV and other immunosuppressive disease have strengthened its prevalence. This research reports small molecule anti-infectives which are specifically potent against several strains and isolates of TB. The hit compound 7f has also proved to be active against almost 25 clinical isolates comparable to marketed anti-TB agents. (C) 2015 Elsevier Masson SAS. All rights reserved.